Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | APLNR | P35414 | 2/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.31 |
| ▸ | OXTR | P30559 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23116041 | 0.84 | CYP1A2 (0.38) | POLBCYP1A2APLNRAVPR1AOXTR | |
| SCHEMBL21835769 | 0.74 | CYP1A2 (0.33) | DGAT1CYP1A2 | |
| SCHEMBL23454243 | 0.71 | DGAT1 (0.31) | DGAT1CYP1A2 | |
| SCHEMBL23454241 | 0.71 | DGAT1 (0.31) | DGAT1CYP1A2 | |
| SCHEMBL23454371 | 0.71 | DGAT1 (0.31) | DGAT1CYP1A2 | |
| SCHEMBL23571599 | 0.69 | MEN1 (0.45) | CYP1A2APP | |
| SCHEMBL24155930 | 0.69 | KDM4E (0.51) | P2RX7POLBCYP1A2 | |
| SCHEMBL23454260 | 0.68 | CYP1A2 (0.35) | CYP1A2 | |
| SCHEMBL23464756 | 0.67 | CYP1A2 (0.38) | CYP1A2APLNRAVPR1AOXTR | |
| SCHEMBL1727075 | 0.65 | ALDH1A1 (0.48) | POLBDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376475-A1 | ION CHANNEL MODULATORS | PRAXIS PREC MEDICINES INC (US) | 2025-12-11 | — | — | US | disclosed |
| CN-119371426-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-119350320-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-4487916-A2 | ION CHANNEL MODULATORS | Praxis Precision Medicines, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240132501-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-04-25 | — | — | US | disclosed |
| US-11866439-B2 | Ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-11731976-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731976-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731978-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731978-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220024930-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220024930-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20210163488-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210163488-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-06-03 | — | — | US | disclosed |
| US-11014931-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014931-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3801535-A1 | ION CHANNEL MODULATORS | Praxis Precision Medicines, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20210087197-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-03-25 | — | — | US | disclosed |
| US-20210087197-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-03-25 | — | — | US | disclosed |
| CN-112423760-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731978-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | SCN1A, SCN3A, CACNA1F | P2RX7 202/4885POLB 4784/4885DGAT1 1960/4885 |
| US-20240132501-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | P2RX7 529/4885POLB 4726/4885DGAT1 596/4885 |
| US-20210087197-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | P2RX7 529/4885POLB 4726/4885DGAT1 596/4885 |
| US-11731976-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | SCN1A, SCN3A, CACNA1F | P2RX7 213/4885POLB 4807/4885DGAT1 2062/4885 |
| US-11866439-B2 | Ion channel modulators | SCN1A, SCN3A, SCN2A | P2RX7 529/4885POLB 4726/4885DGAT1 596/4885 |
| US-20210163488-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | P2RX7 529/4885POLB 4726/4885DGAT1 596/4885 |
| US-20220024930-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | P2RX7 529/4885POLB 4726/4885DGAT1 596/4885 |
| US-11014931-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator | SCN3A, SCN1A, SCN5A | P2RX7 256/4885POLB 4763/4885DGAT1 1531/4885 |
| US-20250376475-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | P2RX7 529/4885POLB 4726/4885DGAT1 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.